Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
105.95
+2.52 (2.44%)
At close: Jan 14, 2026, 4:00 PM EST
105.90
-0.05 (-0.05%)
After-hours: Jan 14, 2026, 7:58 PM EST
Incyte Employees
Incyte had 2,617 employees as of December 31, 2024. The number of employees increased by 93 or 3.68% compared to the previous year.
Employees
2,617
Change (1Y)
93
Growth (1Y)
3.68%
Revenue / Employee
$1,839,169
Profits / Employee
$454,178
Market Cap
20.80B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,617 | 93 | 3.68% |
| Dec 31, 2023 | 2,524 | 200 | 8.61% |
| Dec 31, 2022 | 2,324 | 230 | 10.98% |
| Dec 31, 2021 | 2,094 | 321 | 18.10% |
| Dec 31, 2020 | 1,773 | 317 | 21.77% |
| Dec 31, 2019 | 1,456 | 89 | 6.51% |
| Dec 31, 2018 | 1,367 | 159 | 13.16% |
| Dec 31, 2017 | 1,208 | 228 | 23.27% |
| Dec 31, 2016 | 980 | 288 | 41.62% |
| Dec 31, 2015 | 692 | 104 | 17.69% |
| Dec 31, 2014 | 588 | 107 | 22.25% |
| Dec 31, 2013 | 481 | 68 | 16.46% |
| Dec 31, 2012 | 413 | 45 | 12.23% |
| Dec 31, 2011 | 368 | 121 | 48.99% |
| Dec 31, 2010 | 247 | 26 | 11.76% |
| Dec 31, 2009 | 221 | 9 | 4.25% |
| Dec 31, 2008 | 212 | 16 | 8.16% |
| Dec 31, 2007 | 196 | 10 | 5.38% |
| Dec 31, 2006 | 186 | 9 | 5.08% |
| Dec 31, 2005 | 177 | -9 | -4.84% |
| Dec 31, 2004 | 186 | -268 | -59.03% |
| Dec 31, 2003 | 454 | -37 | -7.54% |
| Dec 31, 2002 | 491 | -94 | -16.07% |
| Dec 31, 2001 | 585 | -737 | -55.75% |
| Dec 31, 2000 | 1,322 | 214 | 19.31% |
| Dec 31, 1999 | 1,108 | 241 | 27.80% |
| Dec 31, 1998 | 867 | 191 | 28.25% |
| Dec 31, 1997 | 676 | 218 | 47.60% |
| Dec 31, 1996 | 458 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INCY News
- 2 days ago - Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 8 days ago - Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins - Seeking Alpha
- 8 days ago - Top 10 Stocks For 2026 - Seeking Alpha
- 9 days ago - Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer - Benzinga
- 9 days ago - Incyte's blood cancer therapy meets main goal in late-stage trial - Reuters
- 9 days ago - Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma - Business Wire
- 23 days ago - Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma - Business Wire
- 23 days ago - Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer - Business Wire